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Simple Summary: Lung cancer is a leading cause of cancer-related death worldwide and in most
cases, detection is usually late and treatment resistance is frequent. For that reason, it is necessary to
find biomarkers that could improve the diagnosis and disease management. Exosomes are a type of
microvesicles secreted by tumor cells to the medium, with important functions in tumor development.
Their analysis can be of utility in diagnosis, including early diagnosis, prognosis, treatment election
or follow-up. However, isolation and analysis are cumbersome and can affect the subsequent data
information. In this review, we will discuss the recent advances in the role of exosomes in lung cancer
and their utility as liquid biopsy, with special attention to isolating methods.
Abstract: Lung cancer is a leading cause of cancer-related death worldwide and in most cases,
diagnosis is reached when the tumor has already spread and prognosis is quite poor. For that reason,
the research for new biomarkers that could improve early diagnosis and its management is essential.
Exosomes are microvesicles actively secreted by cells, especially by tumor cells, hauling molecules
that mimic molecules of the producing cells. There are multiple methods for exosome isolation
and analysis, although not standardized, and cancer exosomes from biological fluids are especially
difficult to study. Exosomes’ cargo proteins, RNA, and DNA participate in the communication
between cells, favoring lung cancer development by delivering signals for growth, metastasis,
epithelial mesenchymal transition, angiogenesis, immunosuppression and even drug resistance.
Exosome analysis can be useful as a type of liquid biopsy in the diagnosis, prognosis and follow-up
of lung cancer. In this review, we will discuss recent advances in the role of exosomes in lung cancer
and their utility as liquid biopsy, with special attention to isolating methods.
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1. Lung Cancer and Exosomes
Lung cancer is a leading cause of cancer-related death worldwide with smoking being
the main risk factor for this disease [1]. This cancer can be divided into two types of
histology, small-cell lung cancer (SCLC), that comprises 15% of the cases, and non-small
cell lung cancer (NSCLC), about 85% of all cases, of which adenocarcinoma and squamous
cell carcinoma are the most common subtypes [2]. About 75% of patients are diagnosed at
locally advanced or even metastatic stage, when the prognosis is considered grim with a
5-year survival rate of only 15%. Thus, lung cancer treatment would greatly benefit from
early detection, as a delayed diagnosis will increase mortality risk.
The understanding of the molecular bases of lung cancer with the discovery of driver
mutations, such as in epidermal growth factor receptor (EGFR) gene in lung adenocarci-
noma [3], and the identification of immune checkpoints that regulate the tumor immune
response [4] have allowed the development of new therapies. As a result, in recent years
important progresses were made in the treatment with EGFR inhibitors, anaplastic lym-
phoma kinase inhibitors, or immune checkpoints inhibitors [3–5]. However, as in other
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malignancies, lung cancer is composed of different cell populations with varied molecular
alterations resulting in tumor and microenvironment heterogeneity [6]. In fact, the initial
predominant targetable alterations can become less abundant during the course of the
disease due to the selection of resistant sub-clones. The identification of these molecular
characteristics during the evolution of the disease is of paramount importance in order to
develop an efficient therapeutic strategy suitable to each clinical situation.
Tumor biopsy is the gold standard diagnostic procedure for histologic and molecular
analysis. However, it is not always feasible due to difficult access to the lesions, and
neither performing repeated biopsies during the course of the disease due to the procedure
invasiveness. Additionally, biopsy may not reflect tumor heterogeneity. For that reason, it
is necessary to find biomarkers with enough sensitivity and specificity for early diagnosis
and for a close monitoring of the disease, helping in the choice of the best therapy for a
personalized medicine. An alternative option to tissue biopsy is to perform the analysis
in liquid biopsy, where repeated sampling can be easily performed [7]. Liquid biopsy in
cancer consists of the analysis of three types of tumor-derived material in biological fluids:
circulating tumor cells (CTCs), tumor-derived extracellular vesicles (EV), mainly exosomes,
and circulating tumor DNA (ctDNA) [8]. Of them, ctDNA has attracted the most attention
and several guidelines already include its analysis for the management of NSCLC [9,10].
Furthermore, some of these treatments mentioned before have already been allowed in
patients with actionable mutations even when detected only in ctDNA [11].
Exosomes are spherical virus-size microvesicles with a density of 1.13–1.21 g/mL
that participate in local and systemic intercellular communication transferring bioactive
molecules between cells (reviewed in [12]). In the case of tumor-derived exosomes, they
contribute to creating a favorable environment for tumor progression [13]. Consequently,
tumor-derived exosomes play an important role in tumor development. Therefore, their
analysis can help to gain a deeper knowledge of tumor biology and they can even be targets
for drug therapy or delivery [14]. In addition, exosomes are very attractive due to their
potential role as cancer biomarkers that could improve the management of cancer patients
in general, and specifically, in lung cancer patients. In this review, we will summarize the
role of exosomes in lung cancer development and their role as biomarkers of diagnosis,
prognosis and even treatment election and follow-up.
2. Exosome Biogenesis and Structure
Cells release several types of microvesicles to the medium that differ in size, cellular
origin and cargo: exosomes (50–200 nm), ectosomes (100–1000 nm) and apoptotic bodies
(500–5000 nm) [15,16]. Exosome biogenesis initiates with the formation of the multivesic-
ular bodies (MVB) containing many intraluminal vesicles formed by invagination of the
endosomal membrane [15,16] (Figure 1). During this process, different materials from
the parent cell, such as DNA, mRNAs, microRNAs (miRNAs), non-coding RNAs, lipids
and proteins are selectively and actively incorporated into them [17]. Their release to the
medium occurs through the fusion of multivesicular bodies with plasmatic membrane [16].
All cells can actively secrete exosomes, but it seems to be especially abundant in the case of
tumor cells, with an estimation of 20,000 vesicles in 48 h by a single cancer cell [18]. Low
oxygen tension and the resulting acidity due to increased glycolysis, typical conditions
found in the tumoral microenvironment, favor the secretion of exosomes by cancer cells [19].
Increased secretion of tumor derived exosomes has been observed during the process of
cancer development [20]. These exosomes can access circulation, where they have a short
half-life and are cleared from blood in 6 h [21]. For example, Rabinowits et al. [22] found
that plasmatic exosome levels were higher in lung adenocarcinoma patients compared to
controls, probably due to alterations in cellular physiology.




Figure 1. Exosome biogenesis, release and uptake from other cells. Exosomes are formed by initial inward budding of 
plasma membrane and the formation on endocytic vesicles. Endosomal vesicles then form multivesicular bodies (MVB), 
which can either be degraded in lysosomes (a) or fused with the plasmatic membrane releasing exosomes to the medium 
(b). Other microvesicles can be formed and shed by simple outward budding of the cell membrane. During exosome 
formation, there is a selective incorporation of RNA, DNA, proteins and lipids, many of them characteristic of the produc-
ing cell. Released exosomes can reach circulation and interact with the target cell by fusion with either the cell membrane 
(I), endocytosis (II), receptor binding (III), or in combination, inducing intracellular signals. 
Exosome membrane is a lipid bilayer especially enriched in lipid rafts, such as those 
of cholesterol, sphingomyelin and ceramide, which makes these microvesicles very stable 
and protected from degradative processes in the extracellular space [23]. Several thousand 
exosomal molecules have already been documented in different databases such as Exo-
carta database (http://www.exocarta.org, accessed on 7 July 2021). Surface proteins in-
clude tetraspanins (CD9, CD63 and CD81), integrins and adhesion molecules or ligands 
that can interact with specific receptors or cells. Other proteins included in exosomes are 
heat-shock proteins (HSP60, HSP70, etc.) as well as others involved in membrane 
transport and fusion (RAB5b, flotillin, annexins, etc.) or in MVB biogenesis (ALG2-inter-
acting protein X, ALIX, and tumor susceptibility gene 101 protein, TSG101). Some of the 
proteins carried by exosomes are characteristic of the producing cells and can help to iden-
tify exosomal origin. For example, trophoblast exosomes can be identified by HLA-G 
transported in them [24], immune cells exosomes transport MHC I and II molecules [25] 
or T lymphocytes exosomes carry CD3 antigen [26]. Similarly, exosomal nucleic acid con-
tent is related to the type of producing cell in addition to the sorting process. Therefore, 
all this complex exosome composition helps to explain their many different roles in inter-
cellular communication, and their potential utility as liquid biopsy. 
3. Exosome Isolation and Identification 
Exosomes have been obtained from different biological fluids, such as serum, plasma, 
urine, cerebrospinal fluid or exudates [27–30]. Exosome isolation methods are mainly 
based on their physicochemical properties, such as size or density, or their biological char-
acteristics and molecules expressed in their surface [31,32]. These methods differ in effi-
ciency, purity, and even in their capability to select exosome subpopulations [33,34]. A 
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plasma membrane and the formation on endocytic vesicles. Endosomal vesicles then form multivesicular bodies (MVB),
which can either be degraded in lysosomes (a) or fused with the plasmatic membrane releasing exosomes to the medium
(b). Other microvesicles can be formed and shed by simple outward budding of the cell membrane. During exosome
formation, there is a selective incorporation of RNA, DNA, proteins and lipids, many of them c aracteristi of th producing
cell. Released exosom s can reach circulati n and interact w th the target by fusion with either the cell membrane (I),
endocytosis (II), receptor binding (III), or in combination, inducing intracellular signals.
Exosome membrane is a lipid bilayer espe ially enriched in lipid raft , such as those
of cholesterol, sphingomyelin and ram de, which makes these microvesicles very stable
and protected from degradative proc sses in the extracellular space [23]. Several thousand
exosom l mol cules have alr ady been documented in different databases such as Exocarta
database (http://www.exocarta.org, accessed o 7 July 2021). Surface proteins i clude
tetraspanins (CD9, CD63 and CD81), integrins and adhesion molecules or ligands that can
interact with specific receptors or cells. Other proteins included in exosomes are heat-shock
proteins (HSP60, HSP70, etc.) as well as others involved in membrane transport and
fusion (RAB5b, flotillin, annexins, etc.) or in MVB biogenesis (ALG2-interacting protein X,
ALIX, and tumor susceptibility gene 101 protein, TSG101). Some of the proteins carried by
exosomes are characteristic of the producing cells and can help to identify exosomal origin.
For example, trophoblast exosomes can be identified by HLA-G transported in them [24],
immune cells exosomes transport MHC I and II molecules [25] or T lymphocytes exosomes
carry CD3 antigen [26]. Similarly, exosomal nucleic acid content is related to the type of
producing cell in addition to the sorting process. Therefore, all this complex exosome
composition helps to explain their many different roles in intercellular communication,
and their potential utility as liquid biopsy.
3. Exosome Isolation and Identification
Exosomes have been obtained from different biological fluids, such as serum, plasma,
urine, cerebrospinal fluid or exudates [27–30]. Exosome isolation methods are mainly
based on their physicochemical properties, such as size or density, or their biological
characteristics and molecules expressed in their surface [31,32]. These methods differ in
efficiency, purity, and even in their capability to select exosome subpopulations [33,34]. A
summary of isolation methods can be found in Table 1 including some of the commercial
kits already available.
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Table 1. Methods for exosome isolation.
Method Isolation Principle
Assessment Parameters
Advantages Disadvantages Examples of Available
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Within the methods based on physicochemical characteristics, ultracentrifugation
procedures are the most widely and traditionally used to isolate exosomes, but isolated
vesicles purity is low as other particles or protein aggregates can also sediment with
them [72]. Besides, there are other important drawbacks such as its cost, the long and
complex process, the difficulty to scale-up the number of samples, and to be used in clinical
settings. Other methods are based on particle size, being the most common ultrafiltration
and size exclusion chromatography [34,54]. Precipitation methods are based on the change
of either their solubility, aggregate formation or both, after the addition of polyethylene
glycol, protamine or sodium acetate [33,65]. Compared to ultracentrifugation procedures,
these methods are less time consuming, do not require large volumes of biological samples
or special equipment, and can be scalable. However, they lack specificity and isolated
exosomes can also be accompanied by impurities. Another more specific method, but quite
costly, is based on the interaction of antibodies with specific molecules at the exosome
surface such as CD81, CD63 or CD9 [31,64]. When using immunocapture assays it should
be considered that their efficiency depends on the number of exosomes, the density of
antigen per particle and the antibody affinity for the exposed epitopes. In fact, not all
antibodies that work properly with free molecules are suitable for exosome capture, as
the target epitope might not be accessible due to the orientation or the folding of the
protein in the exosome [73]. Another important issue is that exosomes can easily adhere to
working material surfaces, with the consequent risk of either losing interesting exosomes,
high background signal or both [13]. Finally, some protocols combine successive isolation
and purification methods, such as polymer precipitation and immunoaffinity purification,
rendering a fairly pure population of exosomes [33,74].
Plasma is one of the most complex fluids and isolated exosomes from it can be
contaminated with particle aggregates, plasma proteins, such as albumin or fibrinogen, or
with similar sized lipoproteins [33,75]. These contaminants can further affect functional
and analytical studies. For example, lipoproteins may carry miRNA that could interfere
when studying these molecules in exosomes [76]. Furthermore, proteomic analysis or even
immunological analysis are prone to provide biased results due to these contaminants [33].
Although many data available are related to tumor exosomes from in vitro experi-
ments, much less are related to tumor specific exosomes obtained from biological fluids.
Blood usually contains high concentrations of exosomes, 108–1011 per mL, but most of them
derive from blood cells, and tumor exosomes usually account for only a small proportion
of the total circulating exosomes, making their isolation cumbersome [77]. The use of
antibodies against exposed tumor antigens at the exosome membrane can be used to purify
cancer exosomes [74]. This procedure can turn out well when specific tumor antigens exist,
such as prostate specific antigen (PSA) in the case of prostate cancer exosomes, but this is
not the case in lung cancer. Tumor marker MUC1, although not specific, is highly expressed
in lung cancer exosomes [78], so it could be an antigen for their selective isolation by
immunoaffinity. Alternatively, the epithelial cell surface molecule (EpCAM) is a frequent
surface biomarker targeted for plasma tumor exosome enrichment in different epithelial
cancers, including lung cancer [22,79].
Unfortunately, there is a lack of consensus on the best method, or even a standardized
procedure for either exosome extraction, purification or both [80]. Related to this, the
exosome isolation method should be taken into account when designing procedures as
it might affect the subsequent experimental results [33]. For example, while in some
experiments, it is necessary to recover the maximal amount of vesicles, and structure
preservation and high purity are not necessary, in others on the contrary, the purity is of
utmost importance. Other important points to consider are the starting volume and the
possibility of scaling up the method, depending on the number of samples to be analyzed.
Depending on the isolation method, it is even difficult to unequivocally distinguish
exosomes from other subgroups of microvesicles from the point of view of their size,
density, morphology, or even biomarkers because these properties overlap between the
different subclasses of microvesicles. Extracellular vesicles (EV) differentiation is difficult
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once released, and for this reason the International Society for Extracellular Vesicles (ISEV)
recommends the use of the term extracellular vesicles when exosomes are not completely
characterized [80].
Related to exosome characterization, the ISEV recommends using multiple com-
plementary techniques to assess the results of extracellular vesicle-isolation methods
(Figure 2) [80,81]. Exosomes can be identified by their size by transmission electron mi-
croscopy (TEM) or nanoparticle tracking analysis (NTA), which also allows measuring
exosome concentration [82,83]. However, these methods do not distinguish exosomes from
other nanoparticles with similar size. Specific exosomal proteins should be used as exo-
some biomarkers in combination with negative protein markers for better characterization.
Membrane proteins, such as CD9, CD63 and CD81, or cytosolic proteins, such as TSG101,
are frequent exosome markers detected by Western blot [80]. Purified EV should be quanti-
fied in terms of total particle number, protein or lipid content, in relation to the starting
material. CD9, CD63 and CD81 have also been used for exosome quantification. Although
they are expected to co-vary, CD63 can vary differently [84]. Furthermore, CD63 is under
present in exosomes compared to cells, while CD81 can be up to 10-fold upregulated in
exosomes [25].




Figure 2. Methods commonly used for extracellular vesicles characterization from biological fluids. According the ISEV 
[80,81], extracellular vesicles should be described by protein markers and single particle characterization by imaging or 
sizing, and also quantified in relation to the source material. 
As mentioned before, it is important to define the source material and the isolation 
method, as they can have an important impact on results, and characterize the extracellu-
lar microvesicles in order to know the purity and recovery [80,85]. For example, Macias et 
al. [33] showed that biomarker detection varied depending on the purification method 
used and there was no correlation in the concentrations of exosomes obtained with differ-
ent procedures. For these reasons, we indicate isolation and characterization methods in 
the following tables showing the clinical utility of exosome biomarkers. 
4. Exosome Function in Lung Cancer 
Secreted exosomes can be captured by other cells by fusion with plasma membrane, 
endocytosis, micropinocytosis, phagocytosis or receptor-mediated specific binding [86]. 
Carried material interacts with target molecules in recipient cells triggering a cellular re-
sponse: exosome mRNA can be translated into proteins [87], miRNA and lncRNA can 
modulate gene transcription and mRNA translation in target cells [88–90], and exosomal 
proteins can interact with receptors [91,92]. These bioactive molecules can induce tumor 
growth and modify cancer microenvironment, thus favoring cancer progression and me-
tastasis [93]. More concretely, exosomes have been implicated in crucial steps of cancer 
development, such as tumor proliferation, epithelial-mesenchymal transition (EMT), tu-
Figure 2. Methods commonly used for extracellular vesicles characterization from biological fluids. According the
ISEV [80,81], extracellular vesicles should be described by protein markers and single particle characterization by i aging
or sizing, and also quantified in relation to the source material.
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As mentioned before, it is important to define the source material and the isolation
method, as they can have an important impact on results, and characterize the extra-
cellular microvesicles in order to know the purity and recovery [80,85]. For example,
Macias et al. [33] showed that biomarker detection varied depending on the purification
method used and there was no correlation in the concentrations of exosomes obtained with
different procedures. For these reasons, we indicate isolation and characterization methods
in the following tables showing the clinical utility of exosome biomarkers.
4. Exosome Function in Lung Cancer
Secreted exosomes can be captured by other cells by fusion with plasma membrane,
endocytosis, micropinocytosis, phagocytosis or receptor-mediated specific binding [86].
Carried material interacts with target molecules in recipient cells triggering a cellular
response: exosome mRNA can be translated into proteins [87], miRNA and lncRNA can
modulate gene transcription and mRNA translation in target cells [88–90], and exoso-
mal proteins can interact with receptors [91,92]. These bioactive molecules can induce
tumor growth and modify cancer microenvironment, thus favoring cancer progression and
metastasis [93]. More concretely, exosomes have been implicated in crucial steps of cancer
development, such as tumor proliferation, epithelial-mesenchymal transition (EMT), tumor
migration and metastases, induction of angiogenesis and immunosuppression (Figure 3).
In the following paragraphs, we will discuss some examples of these mechanisms in
lung cancer.
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cules that can induce signals to stimulate tumor growth or even drive cell transformation 
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and tyrosine kinase inhibitors (TKIs) have become a first-line therapy, although most pa-
tients relapse as drug resistance appears with time [2]. Different works revealed that exo-
somes could participate in the resistance to these drugs transferring miRNA or lncRNA 
from drug-resistant cancer cells to sensitive cells. For example, Zhang et al. [96] showed 
that gefitinib-resistant PC9 cells and their exosomes had high expression of miR-214. 
Those exosomes transferred miR-214 to sensitive PC9 cells that, as a result, acquired re-
sistance. More recently, it was shown that exosomal transference of wild type EGFR pro-
motes resistance to the TKI osimertinib by activating PI3K/AKT and MAPK signaling 
pathways [97]. Consequently, exosomes can also become therapeutic targets to overcome 
resistance development to these drugs. 
Figure 3. Role of exosomes in lung cancer. Tumor exosomes participate in key steps of cancer progression, such as tumor
cell proliferation, epithelial-mesenchymal transition, tumor migration and metastases, induction of angiogenesis and
immune tolerance.
4.1. Exosomes Promote Lung Cancer Growth and Metastasis
Non-controlled cell proliferation is the basis of cancer growth and involves activation
or altered expression of cell cycle genes and proteins. Tumor exosomes can carry molecules
that can induce signals to stimulate tumor growth or even drive cell transformation [94].
miRNAs are the exosomal molecules that have probably been studied more extensively in
relation to the different steps of the metastatic development. As an example, Wu et al. [95]
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showed that H1299 human lung adenocarcinoma cell line secretes miR-96-containing
exosomes that inhibit the expression of LMO7, a tumor suppressor gene in lung cancer, and
promote cell proliferation. Another study showed that A549 lung cancer adenocarcinoma
cell line secretes exosomes engulfing miR-21 and miR-29a that bind Toll-like receptor TLR8
in immune cells, and trigger an NF-κB activation and secretion of inflammatory cytokines,
thus favoring tumor growth and metastasis [88].
Mutations and gene amplifications of EGFR are important in NSCLC development
and tyrosine kinase inhibitors (TKIs) have become a first-line therapy, although most
patients relapse as drug resistance appears with time [2]. Different works revealed that
exosomes could participate in the resistance to these drugs transferring miRNA or lncRNA
from drug-resistant cancer cells to sensitive cells. For example, Zhang et al. [96] showed
that gefitinib-resistant PC9 cells and their exosomes had high expression of miR-214.
Those exosomes transferred miR-214 to sensitive PC9 cells that, as a result, acquired
resistance. More recently, it was shown that exosomal transference of wild type EGFR
promotes resistance to the TKI osimertinib by activating PI3K/AKT and MAPK signaling
pathways [97]. Consequently, exosomes can also become therapeutic targets to overcome
resistance development to these drugs.
An important step in tumor metastasis is EMT in which tumor cells lose their adherent
characteristics of epithelial cells with decreasing expression of epithelial markers like
E-cadherin and occludins, and acquire a mesenchymal phenotype with migratory and
invasive capabilities, overexpressing mesenchymal markers like vimentin, N-cadherin o
ß-catenin [98]. Different studies showed that exosomes participate in EMT in lung cancer
transferring mesenchymal-induced signals and driving tumor cells to a more aggressive
phenotype. For example, Rahman et al. showed that exosomes derived from highly
metastatic lung cancer cells induced vimentin expression and EMT in HBE human bronchial
epithelial cell line [99]. The highly metastatic lung cancer cell line SPC-A-1-BM and its
exosomes were enriched in miR-499a-5p and by transferring this miRNA, these exosomes
could increase the proliferation, migration and EMT via the mTOR pathway [100]. Cancer
associated fibroblasts also secrete exosomes loaded with miR-210 that are uptaken by
lung cancer cells inducing cell migration, proliferation, invasion abilities and EMT [89].
Finally, A549 cells, after TGF-β1-mediated EMT, release exosomes with cargo changes,
both in protein and miRNA content, that induce further phenotypic changes via autocrine
signaling [101].
An initial step for metastasis is the creation of a distant premetastatic niche with a
favorable microenvironment where tumor cells can settle. Exosomes actively participate in
this process, transporting active molecules in circulation that can modify target cells. In
addition, through the carried molecules, particularly integrins, tumor exosomes can specif-
ically target different organs or tissues and prepare the pre-metastatic niche [102]. Lewis
lung carcinoma cell line produces exosomes containing miR-3473b, which once captured by
lung fibroblasts cause NF-kB activation and inflammatory cytokines production, enhancing
their intrapulmonary colonization [103]. Lung cancer commonly metastasizes to the brain
and bone. Gang et al. [104] showed that lung cancer exosomes target brain microvascular
endothelial cells inducing the release of Dkk-1 that provokes a displacement from M1
to a more pro-tumorigenic M2 phenotypic microglia. Subsequently, the metastatic lung
cancer cells decrease Dkk-1 release removing the suppression on microglia that acquire
a supportive phenotype. Furthermore, related to bone metastasis, Taverna et al. [91] ob-
served that NSCLC exosomes contain amphiregulin, which binds EGFR in pre-osteoclasts
activating the pathway that conducts to the expression of proteolytic enzymes initiating
osteoclastic differentiation.
4.2. Exosomes Promote Lung Cancer Angiogenesis
Tumor growth is dependent on the blood supply with nutrients and oxygen, which
requires the development of new vessels from the surrounding tissue. Tumor exosomes
were shown to transport diverse molecules, especially miRNAs that once internalized by
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endothelial cells can induce neoangiogenesis. Hypoxia, which induces exosome release
as we mentioned before, is very common in cancer and favors angiogenesis. For example,
Hsu et al. [105] showed that lung cancer cells in hypoxic conditions secrete exosomes
loaded with miR-23a, which once internalized in endothelial cells produces two effects
in vasculature: first, it enhances angiogenesis by inhibiting prolyl hydroxylase 1 and 2,
which produces accumulation of the hypoxia-inducible factor-1α (HIF-1 α); and secondly, it
increases vascular permeability by inhibiting tight junction protein ZO-1 (zonula occludens
1 protein). Another study showed that exosomes from cigarette smoke extract-transformed
human bronchial epithelial cells have high levels of miR-21 [94]. Exosomes transport this
miR-21 into recipient normal human bronchial epithelial cells and induce elevated vascular
endothelial growth factor (VEGF) levels promoting angiogenesis in human umbilical vein
endothelial cells. Li et al. [106] observed that NSCLC cells overexpress leucine-rich-alpha2-
glycoprotein 1 (LRG1), a protein that induces angiogenesis. Moreover, using the A549
cell line, they showed the release of exosomes loaded with LRG1, which induced, in
endothelial cells, VEGF-A and angiopoietin-1 proangiogenic markers through a TGF-ß
depended mechanism, and enhanced angiogenesis.
4.3. Exosomes Promote Lung Cancer Immune Tolerance
One of the central issues for tumor development is immune evasion through the de-
velopment of a tolerogenic microenvironment avoiding cellular killing, thereby facilitating
tumor progression. Tumor exosomes’ cargo can suppress immune cell function by two
mechanisms in the target cell: either indirectly reprogramming of cells to suppress im-
mune functions in other cells, or directly blocking immune function. Membrane associated
HSP72 from tumor-derived exosomes can bind TLR2 ligand on myeloid-derived suppressor
cells inducing a STAT3-dependent immunosuppressive function [92]. Huang et al. [107]
showed that lung cancer exosomes induce dendritic cells into a tolerogenic phenotype
and, secondarily, naïve CD4+ T cells into tumor antigen-specific regulatory T cells, which
could suppress the tumor antigen specific CD8+ T cells. Similarly, another study showed
that lung tumor cells under hypoxia secrete microvesicles packed with the TGF-ß and
miR-23a, which in turn, inhibit NK cell function decreasing the cell surface expression of the
activating receptor NKG2D and the cytotoxic marker CD107a/LAMP1, respectively [108].
A common mechanism of immune evasion is the upregulation of immune checkpoints
molecules, such as programmed death-ligand 1 (PD-L1), which interact with their cor-
responding receptor in T cell, suppressing the response. Cheng et al. [109] showed that
metastatic melanoma, breast and lung cancer cells release extracellular vesicles, mostly
exosomes, expressing surface PD-L1, whose levels increased after IFN-γ stimulation. Mi-
crovesicle PD-L1 binds PD-1 in the surface of CD8 T cells and suppresses the function, thus
favoring tumor growth.
5. Exosomes as Biomarkers in Lung Cancer
Given the exosomal content, potential biomarkers comprise a wide variety of molecules
including proteins and nucleic acids (Tables 2, 3 and 6) Although initially many of the
studies focused on proteins, in the last few years, miRNAs have attracted growing atten-
tion [110]. In many cases, utility does not rely on a single molecule but on a panel of them
instead. Related to this and as it occurs with many other aspects of biological research,
bioinformatics and big-data analysis have become key players, allowing management and
evaluation of huge quantities of data in the search for the best markers.
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Table 2. Studies on clinical utility of exosomal proteins as biomarkers in lung cancer.
Molecule Sample Number of Subjects Isolation Methods CharacterizationMethods Utility Comments Authors
CD151, CD171, and
tetraspanin 8 Plasma 336 LC + 126 C EV array - Diagnosis
AUC calculated between LC
and controls and when
subdividing in AC, SCC and
SCLC. NYESO1, HER2,
EGFRvIII, SFTPD, Florilin1,





Screening set: 10 C,
10 IP, 14 AC, 12 SCC
Validation set: 54 C,
19 IP, 105 AC, 34 SCC
Immune-affinity for
screening set
ELISA with anti-CD9 in
validation set
- Diagnosis
Screening set: isolation by
immune-affinity with
anti-CD9 tips and proteomic
study to identify CD9
Validation Set: ELISA with
anti CD9 as capture antibody
and anti-CD91 as detection
antibody
Ueda et al. [112]





proteins identified by mass
spectrometry
Niu et al. [113]




and HUWE1 Plasma 13 AC + 15 C Density gradient TEM/NTA/WB Diagnosis
108 differentially expressed

















proteins identified by mass
spectrometry; 55 confirmed
by Western blot. CD5L
highest AUC
Choi et al. [74]
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Table 2. Cont.
Molecule Sample Number of Subjects Isolation Methods CharacterizationMethods Utility Comments Authors
LRG1 Urine 8 NSCLC + 10 C Ultracentrifugation TEM Diagnosis
Differentially expressed
proteins identified by mass
spectrometry
Li et al. [115]
CD171 (1), NY-ESO-1
(2) EDTA Plasma 276 NSCLC EV array -
Prognosis: (1) OS,
(2) HR Array for 49 proteins
Sandfeld-Paulsen
et al. [116]
PD-L1 Plasma 33 NSCLC Precipitation TEM/NTA/WB Prognosis: OS andPFS
Quantification with Simoa
Bead Technology Yang et al. [117]












Abbreviations: AC: adenocarcinoma; AUC: area under ROC curve; BC: breast cancer; C: controls; CEA: carcinoembryonic antigen; CYFRA21-1: cytokeratin 19 fragment; DLS: dynamic light scattering; EDTA:
ethylenediaminetetraacetic acid; EV: extracellular vesicles; HR: hazard ratio; IP: interstitial pneumonia; LC: lung cancer; NSCLC: non-small cell lung cancer; NTA: nanoparticle tracking analysis; OS: overall
survival; P: pneumonia; PFS: progression-free survival; SCC: squamous carcinoma; SCLC: small cell lung cancer; T: tuberculosis; TEM: transmission electron microscopy; TNM: tumor-node-metastasis; WB:
Western blot.
Table 3. Studies on clinical utility of exosomal miRNAs as biomarkers in lung cancer.








Screening set: 10 AC+
10 LG + 10 C
Validation set: 50
AC+ 30 LG + 25 C
Precipitation -










miR-210-5p and miR-1269a Serum
Training set: 74
NSCLC + 74 C
Validation set: 73
NSCLC + 75 C
Precipitation TEM/NTA/WB Diagnosis




Wang et al. [120]
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Table 3. Cont.
Molecule Sample Number of Subjects Isolation Methods CharacterizationMethods Utility Comments Authors
miR-5684 (1) and
miR-125b-5p (1, 2, 3)
+CEA








22 miRNAs profiled by
microarrays and verified
by quantitative PCR
Zhang et al. [121]
miR-23b-3p + CEA +
CYFRA21-1 Serum
80 NSCLC + 60 P +
30 C Precipitation TEM/NTA
Diagnosis
Prognosis: tumor size,





used as the external
reference gene
Wang et al. [122]
let-7f-5p (1)
miR-320a, miR-622 and
let-7f-5p (2) + CEA and
CYFRA21-1
Plasma 80 NSCLC + 30 C Membrane affinityspin columns -
(1) Diagnosis










Zhang et al. [124]






RT-PCR Yang et al. [125]








Testing set: stage I
(16 AC + 10 SCC)
+ 12 C
Validation set: stage I



















Jin et al. [126]
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Table 3. Cont.
Molecule Sample Number of Subjects Isolation Methods CharacterizationMethods Utility Comments Authors




stage I + 34 stage II








miRNA selected with an
array in 6 NSCLC








RT-PCR in 8 randomly
chosen miRNAs






NSCLC + 16 COPD +
16 C
Technical validation
set: 16 NSCLC + 8
COPD + 6 C
External validation
set: 100 NSCLC + 58
C
Precipitation - Diagnosis (includingearly stage)
754 microRNAs screened
with TaqMan Low








miR-182 and miR-210 Pleuraleffusion 41 AC + 15 BPE Precipitation - Diagnosis
miR-21, miR-31, miR-182,









WB Diagnosis Development of aPOCT device Zhou et al. [131]
miR-574-5p and miR-328-3p
and miR-423-3p Plasma
30 NSCLC (16 with
and 14 without bone
metastasis) + 14 C
Ultracentrifugation WB Bone metastasisdetection Small RNA sequencing Yang et al. [132]
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Table 3. Cont.












Relative levels related to
exosomal protein content
Yuwen et al. [133]

















Zheng et al. [134]
hsa-miR-320d, hsa-miR-320c,
and hsa-miR-320b Plasma
5 NSCLC with partial
response to
PD-1/PD-L1
inhibitors + 4 with
progression + 7 C
Ultracentrifugation TEM Response toPD-1/PD-L1 inhibitors
Small RNA profile with
RNA NGS; 155 miRNAs
differentially expressed
versus controls
Peng et al. [135]
Abbreviations: AC: adenocarcinoma; BPE: benign pleural effusion; BPN: benign pulmonary nodules; C: controls; CEA: carcinoembryonic antigen; COPD: chronic obstructive pulmonary disease; CYFRA21-1:
cytokeratin 19 fragment; EV: extracellular vesicles; LC: lung cancer; LG: lung granuloma; miRNA: microRNA; NGS: next generation sequencing; NSCLC: non-small cell lung cancer; NTA: nanoparticle tracking
analysis; OS: overall survival; P: pneumonia; PFS: progression-free survival; PID: pulmonary inflammation diseases; RT-PCR: real-time polymerase chain reaction; SCC: squamous carcinoma; SCLC: small cell
lung cancer; T: tuberculosis; TCGA: The Cancer Genome Atlas; TEM: transmission electron microscopy; TNM: tumor-node-metastasis; WB: Western blot.
Table 4. Studies on clinical utility of exosomal mRNAs, lncRNAs and circRNAs as biomarkers in lung cancer.




Serum 54 AC + 16 SCC Ultracentrifugation TEM/NTA/WB Histologicalclassification
17 miRNAs to be analyzed were
selected previously from TCGA
database as differentially
expressed between AC and SCC.
ACTB and SLC25A6 were used
as internal references
Cao et al. [136]
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Table 5. Studies on clinical utility of exosomal mRNAs, lncRNAs and circRNAs as biomarkers in lung cancer.
Molecule Sample Number of Subjects Isolation Methods CharacterizationMethods Utility Comments Authors





eIF4E data extracted from TCGA
database Dong et al. [137]
PD-L1 (1) and IFN-γ






Quantification by ddPCR with
ACTB as internal control Del Re et al. [138]






GAPDH was used for
normalization
Zhang et al. [90]
linc01125 Serum 277 NSCLC + 187 C +5 P + 59 T + 58 COPD Precipitation -
Diagnosis
Prognosis (stage, OS)
RNA-Seq for lncRNA profile
and subsequent quantification of
linc01125 by RT-PCR with
spiked in controls
Xian et al. [139]
FECR Serum
35 with limited SCLC








RT-PCR with β-actin as control Li et al. [140]
circ_0014235 and
circ_0025580 Plasma 30 SCC + 30 C Precipitation -
Diagnosis
Prognosis (TNM
stage and tumor size)
circRNA sequencing and
confirmation with RT-PCR with
GAPDH as internal control
Wang et al. [141]
circRNA_0056616 EDTA plasma




Precipitation TEM/WB Lymph nodemetastasis predictor
RT-PCR. Normalization as
Wang’s methods He et al. [142]




RT-PCR. GAPDH and U6 were
used as internal references and
cel-miR-39 as an external
reference
Zhang et al. [143]
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Table 6. Studies on clinical utility of exosomal mRNAs, lncRNAs and circRNAs as biomarkers in lung cancer.






NSCLC + 45 C
Training set: 120
NSCLC + 165 C
Validation set 1: 62
NSCLC + 95 C
Validation set 2: 63










identified by RNA-seq, 17 of
them were differentially
expressed and 8 of them were
validated by RT-PCR with
GAPDH and ACTB as spiked-in
controls
Xian et al. [144]
Abbreviations: AC: adenocarcinoma; C: controls; circRNA: circular RNA; COPD: chronic obstructive pulmonary disease; ddPCR: droplet digital PCR; EV: extracellular vesicles; FC: flow cytometry; LC: lung
cancer; miRNA: microRNA; NSCLC: non-small cell lung cancer; NTA: nanoparticle tracking analysis; OS: overall survival; P: pneumonia; PFS: progression-free survival; RT-PCR: real-time polymerase chain
reaction; SCC: squamous carcinoma; SCLC: small cell lung cancer; T: tuberculosis; TCGA: The Cancer Genome Atlas; TEM: transmission electron microscopy; TNM: tumor-node-metastasis; WB: Western blot.
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5.1. Exosomal Proteins
Some of the studies in exosomal protein profiles have been performed using arrays
that allow a multiplex analysis of exosomal proteins but without requiring a previous
exosomes isolation [145]. For example, Sandfeld-Paulsen et al. [111] found that CD151,
CD171 and tetraspanin 8 presented significant differences between controls and multiple
lung cancer histological types, although the associated areas under ROC curve (AUC) for
individual markers were quite limited with a maximum AUC of 0.68. Only when combining
10 markers in a panel could the AUC reach 0.76. Interestingly, some of these proteins,
such as CD91, presented better diagnostic efficiency in other studies when combined with
carcinoembryonic antigen (CEA) [112]. In fact, this and other studies combine exosomal
markers with classical serological markers to achieve better diagnostic efficiencies. For
instance, in another proteomic study of exosomal content, Niu et al. [113] detected higher
levels of alpha-2-HS-glycoprotein (AHSG) and extracellular matrix protein 1 (ECM1) in
serum samples from NSCLC patients when compared with healthy volunteers. In the case
of AHSG, all cancer patients taken into account, the associated AUC was 0.736, which
was reduced when selecting only early-stage patients. Regarding ECM1, both AUCs were
similar and lower than that of AHSG. However, when AHSG was combined with CEA, the
AUCs increased to 0.938 and 0.911, respectively, in total and early-stage NSCLC patients,
substantially improving the efficiency of CEA alone. Meanwhile, Jakobsen et al. [84]
performed this type of analysis with 37 antibodies. When combining CD81, CD63 and
TAG72, the multivariate analysis showed an AUC of 0.758. Only when up to 30 proteins
were included in the analysis, did the AUC reach a value of 0.830. A larger study performed
with mass spectrometry identified 108 proteins with differential expression in exosomes
between lung adenocarcinoma patients and healthy controls. Four of them, SRGN, TPM3,
THBS1 and HUWE1, presented a combined AUC of 0.90 [114]. Another recent study
identified CD5L as another potential biomarker [74]. This protein, an apoptosis inhibitor,
was found to be overexpressed in both exosomes and cancer tissues and presented an AUC
for lung cancer diagnosis of 0.943.
The term liquid biopsy usually refers to peripheral blood samples but other fluids’
analyses are also possible. Of particular interest is urine, which has the advantage of being
less complex than plasma, although there are other issues to consider, such as the contami-
nation from urine proteins or the time of collection. In fact, a recent article was published
with methodological considerations from the Urine Task Force of the International Society
for Extracellular Vesicles for exosome analysis in urine samples [146]. A proteomic study of
lung cancer patients revealed high expression of LRG1 in urinary exosomes and lung tissue,
suggesting that this protein can be a potential biomarker [115]. However, the specificity for
lung cancer is expected to be low as other cancers also express LRG1 [147,148].
Regarding prognosis, Sandfeld-Paulsen et al. [116] observed an association between
NY-ESO-1, EGFR, PLAP, EpCam and Alix from plasma exosomes with poor overall survival,
although only NY-ESO-1 kept the association when Bonferroni correction was applied.
EGFR gene evaluation has already become a key test in lung cancer management
for prognosis and TKIs therapy election [149]. Additionally, EGFR protein evaluation in
exosomes could also be of interest. For example, EGFR is present in 80% of exosomes
purified from the lung cancer biopsies whereas in only 2% of exosomes from patients with
chronic lung inflammation [107].
Another critical aspect of cancer management is therapy monitoring, and some exoso-
mal biomarkers were also evaluated for this scope. For example, Yang et al. [117] showed
that an increase in exosomal PD-L1 indicated response to treatment and better overall
survival. Similarly, exosomal HSP70 is present in membranes of cancer-derived exosomes
but not in exosomes from non-cancerous cells and correlate with HSP70 content within the
tumor biopsies [118]. Moreover, HSP70 has been found useful not only in diagnosis and
prognosis, but also in patients’ follow-up, with increasing levels in patients with disease
progression and decreasing levels in those with partial or total response.
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Table 2 shows a summary of recent clinical studies of the utility of exosomal proteins
as biomarkers in lung cancer.
5.2. Exosomal miRNAs
As mentioned before, exosomal miRNAs have been implicated in lung cancer pro-
gression through multiple mechanisms including promotion of angiogenesis, vascular
permeability and metastasis (reviewed in [150]). Some of these miRNAs were evaluated as
biomarkers, mainly in diagnosis and prognosis (Table 3) [8]. In most cases, clinical utility
does not rely on a specific miRNA but on a panel of multiple miRNAs. A combination of
miR-151a-5p, miR-30a-3p, miR-200b-5p, miR-629, miR-100 and miR-154-3p achieved 96%
sensitivity and 60% specificity in discriminating lung cancer from granuloma patients [119].
Wang et al. established a panel with four miRNAs (miR-9-3p, miR-205-5p, miR-210-5p,
miR-1269a) that could discriminate NSCLC patients from healthy controls with an AUC
of 0.91 (77% sensitivity and 89% specificity) [120]. Among them, miR-1269a presented
the highest discriminatory capacity. Other candidates for being diagnostic biomarkers in
early-stage NSCLC are miR-20b-5p and miR-3187-5p [124].
As exosomal proteins, miRNAs have also been combined with classical biomarkers of
lung cancer. For example, miR-125b-5p’s usefulness has been evaluated as a diagnostic
marker with discrete results when considering all stages (AUC = 0.700) and even lower
when focusing on early-stage patients [121]. Its combination with CEA slightly improved
CEA efficiency from 0.79 to 0.83. In addition, it could discriminate early versus advanced
disease as well as the presence of lymph node and distant metastases. Another miRNA
evaluated is miR-23b-3p that presented a diagnostic efficiency in ROC analysis of 0.915,
much higher than those observed for classical serological markers such as CEA and CYFRA
21-1 [122]. Similarly, another study on miRNAs showed the utility in NSCLC diagnosis of
let-7f-5p miRNA alone and in combination with CEA and CYFRA 21-1 [123]. Although
diagnostic performance for NSCLC of the miRNA let-7f-5p is better compared to other
conventional markers, it has a near perfect classification when combined with them, with
an AUC of 0.981 (sensitivity of 94.7% and specificity of 93.3%).
In some cases, the utility does not rely on individual miRNAs’ levels but on the
ratio between them instead, as in the miR-21/Let-7a ratio that clearly identified lung
cancer patients from healthy volunteers (with sensitivity and specificity of 56% and 100%,
respectively) and from those with pulmonary benign nodules (sensitivity and specificity
were 56% and 82.6%, respectively) [125].
Exosomal miRNA analysis can help not only in diagnosis but also in histological
classification. For example, Jin et al. [126] identified early-stage NSCLC patients with high
sensitivity (80%) and greater specificity (92%) with a panel of miRNAs (let-7b-5p, let-7e-5p,
miR-23a-3p and miR-486-5p). Moreover, these miRNAs allowed histological classification
with miR-181b-5p and miR-361b-5p mainly being expressed in exosomes from adenocarci-
noma patients, and miR-10b-5p and miR-320b in squamous cell carcinoma patients.
Multiple studies have analyzed both diagnostic and prognostic utility of exosomal
miRNAs. For instance, Dejima et al. [127] evaluated miR-21 and miR-4257 and found, not
only higher levels of both miRNAs in NSCLC patients, but also an association with clinical
parameters such as tumor size and TNM stage in the case of miR-21, and with histological
type, lymphatic invasion and TNM stage for miR-4257. Moreover, higher levels of both
miR-21 and miR-4257 were associated with shorter disease-free survival.
Exosomal profile in pleural effusions can also be useful to detect lung malignancies.
In fact, Lin et al. [128] observed that from 254 miRNAs detected in exosomes from pleural
effusions, miR-205-5p and miR-200b could differentiate malignant effusions from those
of pneumonia and tuberculosis patients. These two miRNAs were also included in a
combination of exosomal miRNAs from peripheral blood (miR-429, miR-205, miR-200b,
miR-203, miR-125b and miR-34b) that identified early-stage patients with a sensitivity of
85% and specificity of 74% [129]. More recently, Tamiya et al. [130] identified another pair
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of miRNAs, miR-182 and miR-210, which were able to identify malignant pleural effusions
from benign ones with an AUC in ROC curves of 0.87 and 0.81, respectively.
Development of new and easy-to-use technological devices already allows the transfer
of exosome research to clinical application. For example, a point-of-care device was recently
developed to analyze salivary and urinary miR-205 [131], one of the miRNAs identified
with diagnostic utility in some of the studies mentioned before.
About 20–40% of lung cancer patients develop bone metastasis with a negative impact
in overall survival [151]. Yang et al. [132] identified three exosomal miRNAs with differen-
tial expression in NSCLC patients depending on whether they had bone metastasis or not.
In the case of miR-574-5p, it was downregulated, while miR-328-3p and miR-423-3p were
upregulated. All of them participate in the Wnt/β-catenin signaling pathway and thus can
regulate metastasis development.
Exosomal miRNAs were also evaluated in the context of treatment election and follow-
up. Regarding chemotherapy resistance, Yuwen et al. [133] observed that NSCLC patients
with low expression of miR-146a-5p presented shorter progression-free survival. Moreover,
the overexpression of miR-146a-5p could revert chemoresistance to cisplatin in A549 lung
cancer cells by inhibiting autophagy. Regarding radiotherapy, Zheng et al. [134] showed
that miR-96 can identify lung cancer patients with high efficiency (AUC = 0.97) but it
also presents potential utility to identify radioresistant patients (AUC = 0.75). Another
treatment option that has become a key strategy against lung cancer is immunotherapy,
with PD-1/PD-L1 as one of the targeted checkpoints. Related to this, exosomes can also
inform of the potential response to anti-PD-1 treatments. In a study from Peng et al. [135],
a signature of three miRNAs from the miRNA-320 family could predict the efficacy of
this type of therapy whereas downregulation of miR-125b-5p during treatment identifies
patients in partial response.
5.3. Other Nucleic Acids
Although miRNAs are the most studied nucleic acids in exosomes, other molecules
have also proved their utility as biomarkers in lung cancer patients (Table 6). In this
way, Cao et al. [136] identified four mRNAs contained in exosomes that distinguished
squamous carcinoma and adenocarcinoma. The combination of these mRNAs, tumor
protein P63 (TP63), keratin 5 (KRT5), CEA cell adhesion molecule 6 (CEACAM6) and
surfactant protein B (SFTPB), improved their histological classification capacity. Related
to prognosis, exosomal eIF4E RNA was associated with TNM stage and the presence of
metastases [137]. Furthermore, patients with higher levels presented shorter survival.
RNA analysis allows the detection of EML4-ALK fusion that identifies patients that
would develop resistance to EGFR inhibitors and would be susceptible to being treated
with ALK inhibitors. Brinkmann et al. has observed that exosomal RNA can reflect the
fusion transcript observed in tissue, becoming a potential alternative when tissue biopsies
are not an option [152]. Moreover, exosomal mRNAs could also serve as biomarkers of
immunotherapy efficacy. For instance, Del Re et al. [138] showed that patients receiving
nivolumab or pembrolizumab with high baseline IFN-γ mRNA levels in exosomes had
shorter progression-free survival than those with lower levels. Similarly, patients that
progressed within three months, presented higher levels than those that responded or had
disease stabilization.
Exosomal long non-coding RNAs (lncRNAs) were also evaluated as potential clinical
biomarkers for lung cancer management. For example, in 2017, Zhang et al. [90], showed
the utility of MALAT-1 as a diagnostic biomarker of NSCLC. Moreover, this lncRNA pre-
sented prognostic utility as it correlated with tumor stage and lymphatic metastases. Since
then, multiple lncRNAs’ utility was proved not only in diagnosis and prognosis, but also
as therapy targets (reviewed in [153]). More recently, linc01125 could distinguish NSCLC
cases from disease-free and tuberculosis controls and correlated with an unfavorable over-
all survival [139]. Related to these lncRNAs, there is even a meta-analysis evaluating their
diagnostic capacity [154].
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Given the recent finding of circular RNA, there are far fewer studies assessing their
role in lung cancer, but some of them have proved their utility as potential biomarkers.
For instance, Li et al. showed that FLI1 exonic circular RNA (FECR) was increased in
SCLC patients and it was correlated with the metastatic status [140]. In another study,
circ_0014235 and circ_0025580 presented diagnostic utility to identify squamous cell carci-
noma patients, and were strongly correlated with higher TNM stage and tumor size [141].
circRNA_0056616 also proved its capability to identify patients with lymph node metas-
tasis [142]. Similarly, circSATB2 could also detect lung cancer metastasis [143]. Xian
et al. showed the diagnostic utility of a panel comprising three circRNAs, circ_0047921,
circ_0007761 and circ_0056285, to differentiate NSCLC patients from not only healthy
controls but also from patients with other types of pulmonary diseases. The latter, also
presented prognostic utility [144].
6. Conclusions
Exosomes are important players in lung cancer development participating in tumor
aggressiveness such as in metastasis, with organ polarization to brain and bone, angiogen-
esis, immune escape and even drug resistance. Due to their size and capability to transfer
molecules into target recipient cells, exosomes also postulate as potential drug delivery
vehicles [14]. As the tumor exosomal cargo includes molecules from the releasing cells and
can be detected in circulation, exosomes can serve as non-invasive biomarkers providing a
potential alternative or at least, a complementary tool to conventional biopsy with addi-
tional advantages in the diagnosis, prognosis, therapy election and follow-up. Furthermore,
the analysis of the complex composition of exosomes can provide a multianalyte approach
that could give a dynamic insight into the tumor microenvironment, helping to provide a
more precise and rapid medical intervention. This is important, as the implementation of
different therapeutic strategies, using new cancer drugs discovered in the last years, needs
appropriate biomarkers for guidance. In addition, exosome analysis could help in the
screening and early detection of lung cancer, when patients have better prognosis [113,124],
and some clinical trials are already addressing this issue (www.clinicaltrials.gov). However,
exosome analysis has not been included in clinical guides yet, contrary to ctDNA where
there are already clinical indications for its use as biomarker in lung cancer and some
commercial kits are already available for mutations’ assessment [8,155]. One of the reasons
is the lack of standardized protocols for exosome isolation and analysis, which impairs the
implementation of their analysis in a routine clinical laboratory. Sophisticated technology,
but also affordable and easy-to-use, for exosome analysis would also help to implement
their use. In addition, studies are usually retrospective and with small cohorts and thus,
more prospective studies with larger populations are needed. Finally, it is difficult to select
the exosome biomarkers that correlated better with the clinical situation between different
reported studies. Once these issues are solved, exosomes will probably be key participants
in lung cancer management. To achieve this, it is necessary to develop more translational
research and clinical trials before introducing exosomes in the management of lung cancer.
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